Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Friday, December 29, 2017 10:12:42 AM
HIGH RISK Bio Stock but with significant upside potential if everything goes well . ADCOM meeting on January 10 for Lipocine´s Tlando the potential FIRST Oral product for the treatment of hypogonadism , if outcome is positive the stock will likely jump close or above $10 easily especially because of its low float more infos below and good luck .
Lipocine (LPCN)
Market Cap: $74 Million
Cash: $25.7 Million
Price: $3.50
Shares Out: 21.2 Million
Latest Presentation
files.shareholder.com/downloads/AMDA-2BVSIV/5783990236x0x958103/2EB5BE41-D62A-4270-9634-2DAE6A0E1438/LPCN_11.08.17_long_FINAL__002_.pdf
The previously scheduled Bone, Reproductive and Urologic Drugs Advisory Committee (“BRUDAC”) meeting on January 10, 2018 to discuss the NDA for TLANDO remains unchanged.
The FDA has assigned a new Prescription Drug User Fee Act (“PDUFA”) goal date of May 8, 2018.
TLANDO™: Potential first oral TRT option
-Differentiated product targeting ~$2.0 billion established US TRT market
-Poised to meet and exceed unmet need
finance.yahoo.com/news/lpcn-third-quarter-operational-financial-180000459.html
Summary
LPCN has resubmitted its NDA for Tlando and has been assigned both a PDUFA and AdCom date. We are optimistic that Lipocine can successfully navigate both of these regulatory requirements and obtain FDA approval. Following the anticipated approval, Lipocine will develop the required sales force and find an appropriate partner to commercialize the primary care segment over the following 90 days. Based on this timeline, first sales are anticipated to take place near mid-year 2018. Lipocine will then be able to launch its first product and shift its development efforts towards LPCN 1111 and 1107.
Top Shareholders :
Royce & Associates LP 843 142 3,98%
Mahesh V. Patel, PhD 713 112 3,36%
The Vanguard Group, Inc. 661 337 3,12%
Carlson Capital LP 500 000 2,36%
John W. Higuchi, MBA 475 248 2,24%
DLD Asset Management LP 401 295 1,89%
VHCP Management LLC 386 928 1,83%
BlackRock Fund Advisors 330 684 1,56%
Renaissance Technologies LLC 228 600 1,08%
Millennium Management LLC 193 269 0,91%
insert-text-here
insert-text-here
insert-text-here
Recent LPCN News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 01:35:10 PM
- Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® • PR Newswire (US) • 09/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 03:23:16 PM
- Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 08/27/2024 12:00:00 PM
- Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 • PR Newswire (US) • 08/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 10:20:27 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 10:19:03 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/07/2024 08:05:52 PM
- Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study • PR Newswire (US) • 06/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:00:30 PM
- Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 • PR Newswire (US) • 06/10/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:48:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:45:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:43:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:41:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:39:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:32:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 09:09:23 PM
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 • PR Newswire (US) • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 10:06:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 10:03:08 AM
- Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 • PR Newswire (US) • 05/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 10:15:30 AM
- Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 • PR Newswire (US) • 05/01/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM